Jilin Pharmaceutical reorganization is not in sight

This reporter Mei Ling from Guangzhou March 28, is a long suspension of Jilin pharmaceutical (000545. SZ) on the day of the re-licensing, the shareholders did not bring the joy of a major reorganization, because they had been "numb": four times in three years of reorganization, four times failed.　　"Wolf" to reorganize the way, also let Jilin Pharmaceutical was dubbed "a-share poison" and "most can be fooled by the listed company" name.　　"Jilin Pharma is not a pharmaceutical company anymore because the focus is on restructuring," said the analyst at the time, who advises the pharmaceutical industry in Andhra Pradesh. Fifth time where the road was reorganized. March 22, 2011 Jilin Pharmaceutical Release Company announcement: The company is planning major assets reorganization matters, the company's stock has been suspended from February 25, is currently with the relevant parties on major assets reorganization issues in-depth analysis, argumentation and so on. This is the third time since March Jilin Pharmaceutical issued reorganization announcement, but also its fifth time in three years reorganization announcement.　　The announcement was only 19 days after the last reorganization failed. Before the Jilin Pharmaceutical claims: Under the influence of real estate macro-control, prior to the reorganization with the radio and television group did not have the basis for implementation, the parties to the SFC to apply for the withdrawal of the major assets reorganization of the application document in early 2010, as the fourth reorganization of Jilin Pharmaceutical, Jilin Pharmaceutical to be the Liabilities and related business to the whole sale to Jilin Golden Spring Group, to all shareholders of radio and television real estate shares to buy its own broadcasting property 100% of the stake.　　If the reorganization is completed, Jilin Pharmaceutical will be the whole hollowed out, the original pharmaceutical business package to Jilin Golden Spring, the overall plunge into real estate business. At this time, the cooperation of the radio and television Group to make performance commitments, said it will be in the next three years to achieve net profit of 1.52 billion yuan. Just as the two sides received a bullish investor, last October, the SFC announced a moratorium on the application of restructuring of real estate development enterprises.　　A record of SAP, will be Jilin pharmaceutical back to the original prototype. Earlier, the first reorganization of Jilin Pharmaceutical in September 2007, the first major shareholder Jilin Jin Quan to the Longkou mining industry to sell its holdings of Jilin Pharmaceutical shares. And two months later, the reorganization failed. Then Jilin Pharmaceutical and Shenzhen Fortis Real Estate Group announced a new round of restructuring matters, but one months later, the reorganization and announced failure.　　Six months later, the third reorganization with Green Seashore Potash Group was launched at the unexpected time of the market, and finally was dismissed in a doubt. Three years of reorganization, Jilin Pharmaceutical industry is always following the market hot: mining companies, the real estate market, the 2008 potash fertilizer concept even a miracle when the stock price soared the potash asset speculation. For the reasons for failure, the term of office for several years, but only a media visit to the Jilin Pharmaceutical Chairman Zhang Shoubin said: "Longkou mining failure is because we did not sign with the Shandong Sasac, not in line with the process; Fortis reorganization because the other side thinks the property industry is starting to be bad The reason for the failure of the potash restructuring of Green Seashore is that the project is too big. "For the failure of the fourth reorganization, Jilin Pharmaceutical Dong said: Coincides with national Real estate regulation, the reason for the unsuccessful reorganization is obvious. Four restructurings were defeated. Jilin Pharmaceutical is repeatedly defeated and repeated war, repeatedly defeated. For such frequent but dramatic restructuring reasons, Zhang Shoubin said: "After the sale of the Jilin Pharmaceutical Shell, the group will be able to integrate all the pharmaceutical companies, may have a chance to go public, so as to increase the control."　　"SZ000545 's shell, why will be" master "can't wait to abandon? Stock price ups and downs who is in the profit "now the Jilin pharmaceutical company called pharmaceutical companies are not appropriate." This thing involves something less public. And Jilin Pharmaceutical management is so anxious to sell the shell.　　Whether there is a loss of state-owned assets is a problem, "the morning Light told The Times weekly. For Jilin Pharmaceutical, now imminent perhaps not the fifth time reorganization, but quietly approached the "*st" big cap.　　According to the relevant documents of China Securities Regulatory Commission, if the company operates for two consecutive years of loss, will be special treatment, the crown to the risk of St. January 2011, Jilin Pharmaceutical released 2010 years of Performance notice: 2010 reporting period, the company net profit of 27 million yuan, the basic earnings per share of-0.17 yuan. 2009 Circle Money Net profit is-15.6484 million yuan, earnings per share is 0.10 yuan.　　Has met the "*st" standard. Read the annual report of Jilin Pharmaceutical 2010.5. In the main financial data column, all but two of the total assets and equity capital are negative. The total operating income decreased by 18.79% in the same period, operating profit was-2.121 million yuan, a decrease of 88.72% in the same period, profit of 2.027 million yuan, the same period reduced 89.25%. In the third quarter of 2010 years, Jilin Pharmaceutical business profit is-2.1167 million yuan, net profit is-1.9416 million yuan, earnings per share-0.01 yuan.　　In the first 3 quarters of 2010, the latest total assets were $261.8213 million, with a liability of $255.1231 million. Jilin Pharmaceutical raw materials mainly include acetaminophen, aspirin passed the Quinolones, 2009 Annual report showed that Jilin pharmaceutical sales scale in shrinking, year-on-year decline of 49.82%, at this time, Jilin Pharmaceutical said performance loss due to the impact of raw material price fluctuations, the company will resume normal production in 2010.　　However, 2010.5 Annual report shows that Jilin Pharmaceutical net profit of 2.0274 million yuan. "Every year in the loss, it is not likely to have a hot spot on the pharmaceutical stock hype."　　At the same time, Jilin Pharmaceutical pharmaceutical business can be said to have been nearly no, its own production of products in the market also does not have any advantages, are the general drug in the market, "side of the dawn of the Times weekly reporter said." In the new product launch, the gradual decline in sales of pillar products at the same time, Jilin Pharmaceutical only in a number of restructuring to seize the market eyeball, but not satisfactory. After announcing the fourth reorganization, Jilin Pharmaceutical stock price from 9.18 yuan per share climbed to 13.85 yuan, up to 50.8%. But when the real estate deal was announced, real estate stocksThe line plunged, Jilin Pharmaceutical nearly fell to a halt. With the beginning of the restructuring of Longkou mining industry, Jilin Pharmaceutical stock has risen by as much as 56%, and the restructuring failed, and three times fell.　　The same period, the third reorganization, Jilin Pharmaceutical stock also 4 consecutive trading, and then in failure after the plunge.　　In such a violent fluctuation, a number of cases of reorganization, the institutions have also evacuated Jilin Pharmaceutical, in the 2010.5 Annual report of the top ten shareholders of the Agricultural Bank of China-Xinhua optimal growth stock Securities investment funds and traffic bank-Huaan strategy Preferred Stock Securities investment Fund in the three quarterly bulletin disappeared. When the stock price fluctuation, institutions have left, the last beneficiary is the company's shareholders: in Jilin pharmaceutical second to third reorganization, the second largest shareholder of tomorrow's industrial holdings of 1.9115 million shares and 7.9122 million shares respectively. Analysts pointed out: "The second shareholder of listed companies in the higher price of the reduction, it is inevitable that the company is a false reorganization, pulled up the stock price, high position is true." "" Jilin Pharmaceutical shareholders may also understand that the company's drug business is no improvement, only from the capital market to consider profit, which is actually a very pessimistic management.　　"Side of the dawn of the Times weekly reporter said. Scandals continue to sell shells no longer easy February 14, in the A-share market is good at manufacturing the topic of the Jilin Pharmaceutical explosion scandal: The company's deputy general manager Liu Yu on February 9 by the average price of 7.86 yuan per share through the Shenzhen securities Trading system to buy 1400 shares, and in the next day that February 10 Day to 7.99 yuan per share of the average price sold 350 shares, the profit amount of 45.5 yuan.　　Violating the provisions of listed companies, resulting in short-term illegal transactions. "If it's 450,000 dollars, it might be OK. But this 45.5 yuan this does not care about the profit of the sleeve, can only explain very eagerly want to release out, will not dispute gain and loss.　　This is a kind of confusion and pessimism, is the company to the confusion, "a person in the industry to the Times weekly reporter said."　　And this, the distance Jilin Pharmaceutical announced the fourth reorganization failure, only 11 days apart. In fact, the Jilin pharmaceutical reorganization scandal has been in existence. In the market, Jilin Pharmaceutical almost include the securities market in a variety of misdeeds: the said and the second shareholder tomorrow industrial borrowing inside information to reduce the company's shares, large shareholder sets are nearly tens of millions of drugs, the group of illegal fund-raising ...　　One of the most concerned is the "frequent replacement of mobile phones, perennial not company, never meet with the media," the chairman of Jilin Pharmaceutical Zhang Shoubin missing. In February of this year, Zhang Shoubin, a joint report by its 98 employees, was "already missing," and Liu Lipo also talked about Zhang Shoubin's loss of state-owned assets and collusion between political and business people. Immediately February 28, the explosive material in the process of forensics was taken away by the police. has not yet been described below. And when The Times reporter call Jilin pharmaceutical Dong Zhou, his phone has been in no answer or busy state. Reporter call Jilin pharmaceutical official online phone, but was told: "We are not Jilin pharmaceutical, we are only the Jilin Pharmaceutical Investment Department, other matters we do not know。 "Before the 4 reorganization was only a hot issue at that time, in the search for restructuring direction of the utility of Jilin Pharmaceutical is very obvious." But now Jilin Pharmaceutical restructuring is a farce, we all know is an urgent need to unload the shell. At present, Jilin Pharmacy in a tiger's state, reorganized so many times are not sold out, reputation has a bit smelly, the price may be very low, "side of the morning of the expected Jilin Pharmaceutical" is now just a headless fly, very blind.　　The end may be more miserable. " It's hard to say what will become, or not, the old pharma company that went public in 1993.